American Heart Journal
Volume 157, Issue 5 , Pages 802-804 , May 2009

Getting real with drug-eluting stents: 5-year follow up of a real-world cohort

  • Rahul Sakhuja, MD, MPP

      Affiliations

    • Division of Cardiology, Massachusetts General Hospital, Boston, MA
    • ,
  • Deepak L. Bhatt, MD, MPH

      Affiliations

    • VA Boston Healthcare System and Brigham and Women's Hospital, Boston, MA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, MPH, VA Boston Healthcare System and Brigham and Women's Hospital.

Received 15 December 2008 ,Accepted 20 December 2008.

References 

  1. Haude M, Erbel R, Issa H, et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J. 1993;126:15–22
  2. Colombo A, Hall P, Nakamura S, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676–1688
  3. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665–1671
  4. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical bayesian meta-analysis. Ann Intern Med. 2003;138:777–786
  5. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370:937–948
  6. Applegate RJ, Sacrinty MT, Kutcher MA, et al. “Off-label” stent therapy 2-year comparison of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2008;51:607–614
  7. Kandzari DE, Roe MT, Ohman EM, et al. Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non–ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005;96:750–755
  8. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–2434
  9. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138–1145
  10. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation. 2004;109:701–705
  11. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008;52:1134–1140
  12. de la Torre-Hernandez JM, Alfonso F, Hernandez F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51:986–990
  13. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  14. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056–1061
  15. Chechi T, Vecchio S, Vittori G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis—a new group of high-risk patients. J Am Coll Cardiol. 2008;51:2396–2402
  16. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009–1019
  17. Food and Drug Administration . Circulatory System Devices Advisory Panel Transcript for December 8, 2006, Meeting. Available at http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4253t2.rtfLast accessed November 29, 2008
  18. Bavry AA, Bhatt DL. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet. 2008;371:2134–2143
  19. Garg P, Cohen DJ, Gaziano T, et al. Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol. 2008;51:1844–1853
  20. Goy JJ, Urban P, Seydoux C, et al. Incidence of stent thrombosis and adverse cardiac events 5 years after sirolimus stent implantation in clinical practice. Am Heart J. 2009;157:883–888
  21. Morice MC, Serruys PW, Barragan P, et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol. 2007;50:1299–1304
  22. Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007;356:989–997
  23. Cutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004;110:1226–1230
  24. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998–1008
  25. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584–2591
  26. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678

PII: S0002-8703(09)00131-8

doi: 10.1016/j.ahj.2008.12.022

American Heart Journal
Volume 157, Issue 5 , Pages 802-804 , May 2009

Article Tools